Today: 9 June 2026
JSE All Share hits record close in budget week — what to watch when Johannesburg reopens
28 February 2026
2 mins read

JSE All Share hits record close in budget week — what to watch when Johannesburg reopens

Johannesburg, Feb 28, 2026, 09:42 SAST — The market is closed.

Johannesburg’s FTSE/JSE All Share index wrapped up last week at a new record high, closing Friday at 128,456, up 1.48%. The Top 40 advanced 1.56% to reach 120,296. Resource-heavy stocks powered the move: Sasol surged 16.06% during the session, and Sibanye Stillwater, Harmony Gold, and Impala Platinum all climbed more than 5%.

The week finished with a sharp rally, pushing the All Share up around 4.4% since last Friday’s close. The Top 40 added about 4.8% over that stretch. Moves like these carry weight for the JSE’s heavyweights, given how exposed they are to swings in commodity prices and the rand; either can snap in a heartbeat if global risk sentiment changes.

Moneyweb pointed to stronger commodity prices and a more stable domestic macro outlook, following this week’s budget, as key drivers behind the rally. “As long as commodity prices, notably gold and platinum, continue to rally, the local market should remain well supported,” said Omri Thomas, director at Abax Investments. Moneyweb

Beyond South Africa, the picture dulled heading into Friday’s finish. U.S. equities lost ground as the month wrapped up, with investors juggling nerves about AI, fresh tariff threats, and persistent geopolitical strains. That kind of risk-off move tends to sting both commodities and emerging-market plays simultaneously.

The rand handed back some gains on Friday, dipping roughly 0.3% to 15.9650 against the dollar after fresh month-end domestic figures. “The sentiment around the market seems to remain fairly positive, but could easily turn for the worse,” said Wichard Cilliers, currency strategist at TreasuryONE. Reuters

Eskom plans another 29% cut to electricity tariffs for two struggling ferrochrome producers — Samancor Chrome and the Glencore-Merafe Resources JV — a decision likely to keep these chrome and smelting stocks in the spotlight as trading picks up. Electricity Minister Kgosientsho Ramokgopa said the move aims to protect jobs, with the government targeting 45 smelters in operation by December.

Inflation pressure eased up a bit. South Africa’s producer price index came in at 2.2% year-on-year for January, slipping from 2.9% in December, and registered a 0.2% drop month-on-month. These factory-gate prices often set the tone for consumer inflation down the line, which in turn can shift rate forecasts.

The JSE’s strong performance hasn’t left much cushion for missteps ahead. Any pullback in gold or platinum—or a sharper move from the rand—would likely knock the resource-heavy indices quickly, raising the question of how much of the surge was real inflows rather than just momentum trading.

Markets reopen after the weekend, and traders will be sifting through local data releases: the Absa manufacturing PMI lands Monday, S&P Global PMI comes Wednesday, followed by South Africa’s reserves update on Friday. Eyes are also peeled for bond auction developments, plus the rand’s grip on levels below 16 to the dollar.

At the moment, the cues are straightforward: watch the currency, plus spot prices for oil, platinum, and gold. The first meaningful gauge of last week’s buying interest comes midweek, when PMI numbers hit.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Oracle (ORCL) stock price drops as AI-spending doubts bite again, with March earnings next test
Previous Story

Oracle (ORCL) stock price drops as AI-spending doubts bite again, with March earnings next test

Borsa Istanbul’s BIST 100 ended the week lower — here’s what matters before Monday’s open
Next Story

Borsa Istanbul’s BIST 100 ended the week lower — here’s what matters before Monday’s open

Go toTop